Heparin News and Research

RSS

Heparin, a highly-sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machines. Pharmaceutical grade heparin is derived from mucosal tissues of slaughtered meat animals such as porcine (pig) intestine or bovine (cow) lung.

Baxter's multiple-dose vial Heparin linked to severe allergic reactions

The U.S. Food and Drug Administration announced today that Baxter Healthcare Corporation has temporarily stopped manufacturing multiple-dose vials of the injectable blood-thinning drug heparin due to reports of serious allergic reactions and hypotension (low blood pressure) in patients who receive high "bolus" doses of the drug.

11 Feb 2008

FDA warns public of contaminated pre-filled syringe flushes

The U.S. Food and Drug Administration (FDA) has announced a nationwide recall of all lots of heparin and saline pre-filled flush syringes manufactured by AM2 PAT, Inc., of Angier, N.C. Two lots have been found to be contaminated with Serratia marcescens, a bacterium that can cause serious injury or death.

28 Jan 2008

New approach to cadmium induced hepatoxicity

Cadmium comes from a wide variety of sources in the environment and from industry and is extremely toxic to humans.

17 Jan 2008

How asthma and allergy symptoms are triggered

In demonstrating that a group of calcium ion channels play a crucial role in triggering inflammatory responses, researchers at Beth Israel Deaconess Medical Center (BIDMC) have not only solved a longstanding molecular mystery regarding the onset of asthma and allergy symptoms, but have also provided a fundamental discovery regarding the functioning of mast cells.

15 Jan 2008

Contaminated syringes make 40 people sick

An investigation is being carried out by the Centers for Disease Control and Prevention (CDC) into blood infections linked to medical syringes which were contaminated with bacteria.

19 Dec 2007

Safe and effective therapy discovered for patients with protein-losing enteropathy

Researchers at the Burnham Institute for Medical Research (Burnham Institute) have developed the first model to study intestinal protein leakage in mice, allowing the team to control and replicate both genetic deficiencies and environmental damages in an in vivo setting.

10 Dec 2007

Anticoagulant bivalirudin following angioplasty in heart attack patients reduces adverse events and bleeding

Late-breaking data presented at TCT 2007, the scientific symposium of the Cardiovascular Research Foundation (CRF), show that the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduces net adverse clinical events by 24 percent compared to the standard treatment, and significantly reduces major bleeding that occurs after angioplasty by 40 percent.

24 Oct 2007

Landmark stent trial to be presented at TCT 2007

The Cardiovascular Research Foundation (CRF) will release results of its landmark research study, HORIZONS AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) at the nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

16 Oct 2007

New synthetic version of the drug heparin

Researchers at the University of North Carolina at Chapel Hill have patented a synthetic version of the drug heparin, called Recomparin, that is less complex chemically and should be easier to produce than previous forms.

24 Sep 2007

Phase 3 study on novel oral direct thrombin inhibitor

Boehringer Ingelheim has announced that the September 15 issue of The Lancet will publish results from the RE-NOVATE study, which investigated dabigatran etexilate as a potential therapy for patients undergoing total hip replacement surgery.

13 Sep 2007

New minimally-invasive coated vascular stent graft in use at Methodist DeBakey Heart Center

Surgeons at the Methodist DeBakey Heart Center in Houston were among the first in the U.S. to implant a new, less-invasive stent graft designed to reduce the risk of blood clots in patients treated for peripheral arterial disease (PAD), which affects as many as 12 million Americans over the age of 50.

11 Sep 2007

Studies assess blood clot prevalence outside hospital prevention in hospital

More cases of venous thromboembolism are diagnosed in the three months following hospitalization than during hospitalization, but less than half of inpatients receive medications to prevent blood clots from occurring, according to a report in the July 23 issue of Archives of Internal Medicine.

24 Jul 2007

Study questions risks of aprotinin during heart surgery

Contrary to recent studies, proper use of a drug called aprotinin to reduce bleeding during heart surgery does not increase the risk of heart attack or stroke, according to a study in the June issue of The Journal of Thoracic and Cardiovascular Surgery.

1 Jun 2007

Proper use of aprotinin to reduce bleeding during heart surgery does not increase the risk of heart attack or stroke

The study was prompted by recent reports suggesting an increased risk of complications including heart attacks, strokes, and kidney problems in patients who received aprotinin to reduce bleeding during heart bypass or valve replacement surgery.

30 May 2007

FDA approves new indication for FRAGMIN for the extended treatment of symptomatic venous thromboembolism

The U.S. Food and Drug Administration (FDA) has approved a new indication for FRAGMIN (dalteparin sodium injection), for the extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence of VTE in patients with cancer.

4 May 2007

Improving outcomes for patients with acute coronary syndrome

Recent changes in the recommended treatments used for patients hospitalized for acute coronary syndromes, such as a heart attack, are associated with reductions in the rates of heart failure, stroke, heart attack and death, according to a study in the May 2 issue of JAMA .

2 May 2007

Efforts to standardize heart care are working

People who suffer a heart attack or severe chest pain today are much less likely to die, or to experience long-lasting effects, than their counterparts even a few years ago, according to a new international study in the May 3 issue of the Journal of the American Medical Association.

2 May 2007

Sticking with guidelines for acute coronary syndromes benefits even very elderly patients

Some say age 90 is the new age 70. If so, there's never been a better time for elderly patients to discuss with family and physicians just how aggressive medical care should be in case of a threatened or definite heart attack.

24 Apr 2007

Micell Technologies presents data on novel drug-eluting stents

Micell Technologies has announced that the Company will be presenting data on use of its supercritical fluid (SCF) surface modification technology for drug-eluting stents at the upcoming Society for Biomaterials 2007 Annual Meeting, April 19-21 2007 in Chicago, Illinois.

19 Apr 2007

Scientists isolate enzyme that could be used to predict survival for nasopharyngeal cancer

Mayo Clinic Cancer Center scientists, in collaboration with Chinese researchers, have isolated an enzyme that could be used to predict survival and recurrence rates for nasopharyngeal cancer -- a common cancer affecting people from Southeast Asia.

18 Apr 2007